Fig. 5

Relationship between risk models and genomic alterations A Pathway annotation of DEGs between risk groups. B Analysis of differences in activation of 14 typical cancer-related pathways in the high- and low-risk group, the significance of the difference was analyzed by Wilcoxon signed rank test. C Analysis of differences in TMB between two risk groups, the significance of the difference was analyzed by Wilcoxon signed rank test. D E The mutation landscape of patients in the TCGA-LIHC cohort (show the top 20 genes) about the high- and low-risk groups. F Display of mutation genes information with significant differences between risk groups. G Display of mutation sites of TP53 differences between high- and low-risk groups. Display CNV information of high H and low I risk groups. J Analysis of differences in fraction genome altered between two risk groups, the significance of the difference was analyzed by Wilcoxon signed rank test. K Analysis of differences in HRD score between two risk groups, the significance of the difference was analyzed by Wilcoxon signed rank test. Analysis of tumor cell stemness index based on methylation L and epigenetic regulation characteristics M between two risk groups, the significance of the difference was analyzed by Wilcoxon signed rank test. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS means non-significant)